SAMUEL BRODER was named executive vice president of scientific and public affairs at the Intrexon Corporation. The former director of NCI was most recently chairman of Intrexon's health sector.
THE PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE appointed 10 members to a new Advisory Panel on Clinical Trials. The panel will convene for its first meeting May 1 in Washington, D.C.
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH has named its 2014 class of elected fellows of the AACR Academy. The fellows will be inducted at the association's annual meeting in San Diego, April 5-9.
The Japan Ministry of Health, Labor and Welfare granted approval to the Lonsurf combination tablet T15 and T20 (trifluridine and tipiracil hydrochloride), for the treatment of patients with unresectable advanced or recurrent colorectal cancer, if refractory to standard therapies.
The European Commission approved a subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
THE RESEARCH!AMERICA Advocacy Awards was held March 12 in Washington, D.C., recognizing individuals and organizations are those whose leadership efforts have been notably effective in advancing our nation's commitment to research.
THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO signed an agreement with Advaxis Inc. to evaluate several new immunotherapy constructs, each built on Advaxis proprietary technology.
THE AMERICAN SOCIETY OF HEMATOLOGY announced 15 research investigators who will receive critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the NIH amid severe funding reductions.
ARTHUR CAPLAN received the 2014 Public Service Award from the National Science Board. Caplan is the founding head of the Division of Bioethics at New York University Langone Medical Center.
THE OHIO STATE UNIVERSITY signed a licensing agreement with MedVax Technologies Inc., for the licensing of cancer peptide vaccine technologies.
